Expectations are also rising for revitalization of the combination drug market along with the expansion of combined benefits for the drug SGLT-inhibitors.

According to related industries, pharmaceutical companies with SGLT-2 inhibitors and DPP-4 inhibitors, such as Beringer Ingelheim, AstraZeneca, and MSD, will go through the registration process of the complex when discussions on expanding the combined diabetes benefits are completed.

However, it is expected that there will be differences in the actual registration speed due to the expiration of patents.

◆Esglito, co-developed by Beringer Ingelheim =Beringer Ingelheim and Lilly, is a combination of SGLT-2 inhibitor